Using AI and MRI to predict treatment response in advanced rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop a deep learning model that utilizes multi-parameter magnetic resonance imaging (MRI) to predict the effectiveness of neoadjuvant therapy in patients with locally advanced rectal cancer. By combining dynamic contrast-enhanced (DCE) imaging with conventional MRI, the study seeks to create a robust model for assessing treatment response and compare it with traditional MRI diagnostic methods. The ultimate goal is to accurately evaluate patients' complete response to treatment and enhance clinical decision-making.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical suspicion or colonoscopic pathology of rectal cancer
* Age over 18 years
* Informed consent and signed informed consent form

Exclusion Criteria:

* Poor magnetic resonance image quality, such as severe artifacts
* Previous treatment for rectal cancer
* History or combination of other malignant tumours
* Not Locally Advanced Rectal Cancer (LARC)
* Not received neoadjuvant therapy or not completed neoadjuvant therapy
* No surgery
* Time interval between MRI and surgery was more than 2 weeks
* Patients were lost to follow-up and voluntarily withdrew from the study due to adverse reactions or other reasons

Where it's running

• Sixth Affiliated Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting
• The First Affiliated Hospital of Jinan University
  Guangzhou, Guangdong, China Not yet recruiting
• The Second Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Not yet recruiting
• Fifth Affiliated Hospital, Sun Yat-sen University
  Zhuhai, Guangdong, China Not yet recruiting

Study contacts

• Study coordinator: Xiaochun Meng
• Email: mengxch3@mail.sysu.edu.cn
• Phone: 13719166488

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Rectal cancer registry to track real-world treatments and outcomes

  This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.

  Recruiting at 2 sites Austrian Breast & Colorectal Cancer Study Group · Wiener Neustadt, Lower Austria and 5 other locations · NCT07780305

• Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery

  This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.

  Recruiting Biruni University · Istanbul · NCT07732894

• Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer

  This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.

  Recruiting at 2 sites Medical University of Gdansk · Limoges and 2 other locations · NCT07669298

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.